Thought Leadership

Latest Report

Thumbnail

Evaluate Vantage Report: US Approvals Under the Spotlight

On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose confirmatory trials have failed. Will the US FDA's standards change after years of apparent leniency? 'US Approvals Under the Spotlight', the latest report from Evaluate Vantage,…

Report library

Thumbnail

Evaluate Pharma Orphan Drug Report 2020

What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…

Thumbnail

Evaluate Vantage 2020 Preview

The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…